PriceTargets.com logo

Inogen - INGN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.67
  • Forecasted Upside: 92.76%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.09 As of 04/18/2024 05:00 PM ET
▲ +0.14 (2.01%)

This chart shows the closing price for INGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INGN

Analyst Price Target is $13.67
▲ +92.76% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Inogen in the last 3 months. The average price target is $13.67, with a high forecast of $26.00 and a low forecast of $7.00. The average price target represents a 92.76% upside from the last price of $7.09.

This chart shows the closing price for INGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Inogen. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2024Needham & Company LLCReiterated RatingHoldLow
2/15/2024William BlairUpgradeMarket Perform ➝ OutperformLow
11/8/2023JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$8.00 ➝ $7.00Low
8/8/2023Stifel NicolausLower TargetHold ➝ Hold$15.00 ➝ $8.00Low
8/8/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$15.00 ➝ $8.00Low
7/13/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
4/20/2023Needham & Company LLCReiterated RatingBuy$26.00Low
2/24/2023Needham & Company LLCLower TargetBuy$36.00 ➝ $26.00Low
1/17/2023William BlairDowngradeOutperform ➝ Market PerformLow
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$32.00 ➝ $22.00Low
11/2/2022Needham & Company LLCLower TargetBuy$45.00 ➝ $36.00Low
5/9/2022Stifel NicolausLower Target$40.00 ➝ $30.00High
12/9/2021Needham & Company LLCUpgradeHold ➝ Buy$47.00High
11/8/2021Stifel NicolausLower TargetHold$70.00 ➝ $40.00High
11/5/2021SVB LeerinkLower TargetMarket Perform$72.00 ➝ $42.00High
11/2/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$71.00 ➝ $45.00Medium
8/8/2021Needham & Company LLCReiterated RatingHoldMedium
7/20/2021SVB LeerinkReiterated RatingMarket PerformMedium
6/4/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
5/5/2021SVB LeerinkBoost TargetMarket Perform$67.00 ➝ $72.00High
5/5/2021KeyCorpBoost TargetPositive ➝ Overweight$60.00 ➝ $75.00High
2/25/2021SVB LeerinkBoost TargetMarket Perform$47.00 ➝ $54.00High
12/14/2020KeyCorpUpgradeSector Weight ➝ Overweight$60.00High
11/13/2020Needham & Company LLCReiterated RatingHoldMedium
8/5/2020SVB LeerinkLower TargetMarket Perform$42.00 ➝ $35.00High
7/23/2020Needham & Company LLCDowngradeBuy ➝ HoldHigh
6/10/2020William BlairDowngradeOutperform ➝ Market PerformHigh
6/1/2020SVB LeerinkBoost TargetMarket Perform$42.00 ➝ $56.00Medium
5/6/2020SVB LeerinkLower TargetMarket Perform$68.00 ➝ $56.00High
5/6/2020Needham & Company LLCLower TargetBuy$80.00 ➝ $75.00High
2/26/2020JPMorgan Chase & Co.Lower TargetUnderweight$60.00 ➝ $45.00High
12/20/2019JPMorgan Chase & Co.Boost TargetUnderweight$47.50 ➝ $60.00Low
11/22/2019Needham & Company LLCReiterated RatingBuy$90.00Low
11/6/2019Needham & Company LLCUpgradeHold ➝ Buy$90.00Medium
8/8/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$78.00 ➝ $47.00High
8/7/2019KeyCorpReiterated RatingHoldMedium
8/7/2019Piper Sandler CompaniesLower TargetOverweight$140.00 ➝ $80.00High
8/7/2019Stifel NicolausDowngradeBuy ➝ Hold$85.00 ➝ $48.00High
8/7/2019Needham & Company LLCDowngradeBuy ➝ HoldLow
7/3/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$72.00Low
6/28/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$111.00 ➝ $91.00High
5/8/2019Stifel NicolausLower TargetBuy$160.00 ➝ $85.00High
5/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$175.00 ➝ $72.00High
5/8/2019Needham & Company LLCLower TargetStrong-Buy ➝ Strong-Buy$191.00 ➝ $111.00Medium
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 4 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Inogen logo
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Read More

Today's Range

Now: $7.09
Low: $6.77
High: $7.20

50 Day Range

MA: $7.67
Low: $6.29
High: $10.15

52 Week Range

Now: $7.09
Low: $4.13
High: $14.10

Volume

346,206 shs

Average Volume

576,685 shs

Market Capitalization

$165.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Inogen?

The following equities research analysts have issued research reports on Inogen in the last twelve months: JPMorgan Chase & Co., Needham & Company LLC, Stifel Nicolaus, StockNews.com, and William Blair.
View the latest analyst ratings for INGN.

What is the current price target for Inogen?

3 Wall Street analysts have set twelve-month price targets for Inogen in the last year. Their average twelve-month price target is $13.67, suggesting a possible upside of 92.8%. Needham & Company LLC has the highest price target set, predicting INGN will reach $26.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $7.00 for Inogen in the next year.
View the latest price targets for INGN.

What is the current consensus analyst rating for Inogen?

Inogen currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INGN, but not buy more shares or sell existing shares.
View the latest ratings for INGN.

What other companies compete with Inogen?

Other companies that are similar to Inogen include Envoy Medical, CollPlant Biotechnologies, Vicarious Surgical, Sanara MedTech and Milestone Scientific. Learn More about companies similar to Inogen.

How do I contact Inogen's investor relations team?

Inogen's physical mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company's listed phone number is (805) 562-0500 and its investor relations email address is [email protected]. The official website for Inogen is www.inogen.com. Learn More about contacing Inogen investor relations.